publicações selecionadas
-
artigo académico
- Manifestations of Anxiety, Cognition and Mood functions in the CMVMJD135 Mouse Model of MJD/SCA3. Elife. 2026
- Allosteric Modulation of Pathological Ataxin-3 Aggregation: A Path to Spinocerebellar Ataxia Type-3 Therapies. Advanced Science. 2025
- Rescue of respiratory and cognitive impairments in Rett Syndrome mice using NLX-101, a selective 5-HT1A receptor biased agonist. Biomedicine & Pharmacotherapy. 2025
- Human platelet lysate supports SH-SY5Y neuroblastoma cell proliferation and differentiation into a dopaminergic-like neuronal phenotype under xenogeneic-free culture conditions. African Journal of Biotechnology. 2024
- Glucocorticoid receptor-dependent therapeutic efficacy of tauroursodeoxycholic acid in preclinical models of Spinocerebellar ataxia type 3. Journal of Clinical Investigation. 2024
- Glucocorticoid receptor-dependent therapeutic efficacy of tauroursodeoxycholic acid in preclinical models of Spinocerebellar ataxia type 3 (IF: 19.47). The Journal of Clinical Investigation. 2024
- Regulation of neuronal mRNA splicing and Tau isoform ratio by ATXN3 through deubiquitylation of splicing factors. Cells. 2023
- Treating Parkinson's Disease with Human Bone Marrow Mesenchymal Stem Cell Secretome: A Translational Investigation Using Human Brain Organoids and Different Routes of In Vivo Administration.. Cells. 2023
- Mitochondrial Dysfunction and Decreased Cytochrome c in Cell and Animal Models of Machado-Joseph Disease. Cells. 2023
- Genetic Ablation of Inositol 1,4,5-Trisphosphate Receptor Type 2 (IP3R2) Fails to Modify Disease Progression in a Mouse Model of Spinocerebellar Ataxia Type 3. International Journal of Molecular Sciences. 2023
- Cell-based therapeutic strategies for treatment of spinocerebellar ataxias: an update. Neural Regeneration Research. 2023
- Assessment of the gastrointestinal fate of bacterial nanocellulose and its toxicological effects after repeated-dose oral administration. Environmental Science-Nano. 2023
- Intrathecal Injection of the Secretome from ALS Motor Neurons Regulated for miR-124 Expression Prevents Disease Outcomes in SOD1-G93A Mice. Biomedicine. 2022
- Cerebellar neuronal dysfunction accompanies early motor symptoms in spinocerebellar ataxia type 3. Disease Models & Mechanisms. 2022
- Profiling Microglia in a Mouse Model of Machado-Joseph Disease. Biomedicine. 2022
- Integration of behavior and neuronal physiology in a mouse model of Rett Syndrome: a focus on serotonergic system modulation. Journal of Neurochemistry. 2022
- Microglial Depletion Has No Impact on Disease Progression in a Mouse Model of Machado-Joseph Disease. Cells. 2022
- MorphData: Automating the data extraction process of morphological features of microglial cells in ImageJ. International Journal of Medical Microbiology. 2022
- Pre-clinical study of a 5HT1A specific agonist in the CMVMJD135 mouse model of Machado-Joseph disease. Journal of Neurochemistry. 2022
- The molecular tweezer CLR01 reduces motor impairments and neuropathology in spinocerebellar ataxia type 3 in vivo models. Journal of Neurochemistry. 2022
- The study of depression and cognitive comorbidities in a mouse model of spinocerebellar ataxia type 3. Journal of Neurochemistry. 2022
- Preclinical Assessment of Mesenchymal-Stem-Cell-Based Therapies in Spinocerebellar Ataxia Type 3. Biomedicine. 2021
- Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response. International Journal of Molecular Sciences. 2021
- IP 3 R2 null mice display a normal acquisition of somatic and neurological development milestones. European Journal of Neuroscience. 2021
- Corrigendum to Neurotoxic effects of MPTP on mouse cerebral cortex: Modulation of neuroinflammation as a neuroprotective strategy¿ [Mol. Cell. Neurosci., Volume 96, April 2019, Pages 1¿9.](S1044743118303907)(10.1016/j.mcn.2019.01.003). Molecular and Cellular Neuroscience. 2021
- Splenic sympathetic signaling contributes to acute neutrophil infiltration of the injured spinal cord. Journal of Neuroinflammation. 2020
- Polyglutamine spinocerebellar ataxias: emerging therapeutic targets. Expert Opinion on Therapeutic Targets. 2020
- Deficiency in classical nonhomologous end-joining-mediated repair of transcribed genes is linked to SCA3 pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2020
- Pre-Clinical Assessment of Mesenchymal Stem Cell-Based Therapies in Spinocerebellar Ataxia Type 3. Food Packaging and Shelf Life. 2019
- Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease. Molecular Neurobiology. 2019
- Neurotoxic effects of MPTP on mouse cerebral cortex: Modulation of neuroinflammation as a neuroprotective strategy. Molecular and Cellular Neuroscience. 2019
- A glucocorticoid receptor-dependent mechanism of bile acid action with therapeutic impact in polyglutamine disease. Journal of Neurochemistry. 2019
- Autologous transplantation of intestine-isolated glia cells improves neuropathology and restores cognitive deficits in beta amyloid-induced neurodegeneration. Glia. 2019
- Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease. Molecular Neurobiology. 2018
- Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease. Molecular Neurobiology. 2018
- Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3. Movement Disorders. 2018
- Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts. Medicinal Research Reviews. 2017
- Absence of Tau triggers age-dependent sciatic nerve morphofunctional deficits and motor impairment. Aging Cell. 2016
- Combined therapy with m-TOR-dependent and -independent autophagy inducers causes neurotoxicity in a mouse model of Machado-Joseph disease. Neuroscience. 2016
- Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain. 2015
- Limited Effect of Chronic Valproic Acid Treatment in a Mouse Model of Machado-Joseph Disease. PLoS ONE (IF=3.234). 2015
- Differential mtDNA Damage Patterns in a Transgenic Mouse Model of Machado-Joseph Disease (MJD/SCA3).. Journal of Molecular Neuroscience. 2015
- Dominant negative effect of polyglutamine expansion perturbs normal function of ataxin-3 in neuronal cells. Human Molecular Genetics. 2015
- Selective impact of Tau loss on nociceptive primary afferents and pain sensation. Experimental Neurology. 2014
- Lithium Chloride Therapy Fails to Improve Motor Function in a Transgenic Mouse Model of Machado-Joseph Disease. Cerebellum. 2014
- Chronic Treatment with 17-DMAG Improves Balance and Coordination in A New Mouse Model of Machado-Joseph Disease. Neurotherapeutics. 2014
- Patterns of mitochondrial DNA damage in blood and brain tissues of a transgenic mouse model of Machado-Joseph disease. Neurodegenerative Diseases. 2013
- Monoamine deficits in the brain of methyl-CpG binding protein 2 null mice suggest the involvement of the cerebral cortex in early stages of Rett syndrome. Neuroscience. 2010
- Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Neurobiology of Disease. 2010
- Genotype-Phenotype Correlation in a Transgenic Mouse Model of Machado-Joseph Disease. Neurology. 2009
- Region-Specific Changes in the Expression of Hsp70 in the Central Nervous System of a Transgenic Mouse Model of Machado-Joseph Disease. Neurology. 2009
-
artigo de conferência
- Befiradol treatment ameliorated the motor dysfunction of Spinocerebellar Ataxia Type 3 mouse model 2022
- Pre- clinical study of a 5HT1A specific agonist in the CMVMJD135 mouse model of Machado– Joseph disease 2022
- The molecular tweezer CLR01 reduces motor impairments and neuropathology in spinocerebellar ataxia type 3 in vivo models 2022
- Neuronal missplicing and imbalance in tau isoform ratio through atxn3 mediated deubiquitylation: implications for disease 2019
-
documento
- The therapeutic potential of TUDCA in stress-related brain pathologies 2025
- The therapeutic potential of tauroursodeoxycholic acid in stress-related brain pathologies 2025
- From central to peripheral perspectives in Machado-Joseph Disease: disentangling new therapeutic avenues 2025
- Skeletal muscle alterations as an early pathological manifestation in a mouse model of Machado-Joseph disease 2025
- Therapeutic efficacy of chronic 5-HT1A receptor agonism by NLX-112 (befiradol) in Spinocerebellar Ataxia Type 3 mice 2025
- ATXN3 is A Key Regulator of Neuronal Splicing and Tau Isoform Dynamics 2024
- Therapeutic efficacy of chronic 5-HT1A receptor agonism by NLX-112 (befiradol) in Spinocerebellar Ataxia Type 3 mice 2024
- Characterization of the movement disorder phenotype of a mouse model of Down Syndrome 2024
- Involvement of skeletal muscle in Spinocerebellar ataxia type 3: contribution to disease, potential for biomarker development and therapeutic targeting 2024
- Selective biased agonism of 5-HT1AR rescues respiratory and cognitive impairments but not the movement disorder component in Rett Syndrome mice 2024
- Therapeutic efficacy of chronic 5-HT1A receptor agonism by NLX-112 (befiradol) in Spinocerebellar Ataxia Type 3 mice" 2024
- Understanding the regulation of stress responses in a mouse model of SCA3 2024
- ATXN3-mediated deubiquitylation of splicing factors regulates neuronal mRNA splicing and tau isoform ratio ATXN3 regulates SRSF7 levels and Tau ratio 2023
- Serotonin as an endogenous regulator of proteostasis: towards mechanism 2023
- The skeletal muscle in SCA3: contribution to disease, potential for biomarker development and therapeutic target 2023
- Assessing the HPA-axis mediated stress responses in a mouse model of SCA3 2023
- Therapeutical potential of tauroursodeoxycholic acid in stress-related brain pathologies 2023
- The glucocorticoid receptor as a biomarker and neuronal therapeutic target of a disease-improving bile acid in SCA3/MJD 2023
- Unraveling the ATXN3 interactome: clues on its contribution for physiology and disease 2023
- Limited Therapeutic Impact of Intermittent Fasting and Ketogenic diets in a Mouse Model of Spinocerebellar Ataxia Type 3 2023
- Glucocorticoid Receptor as a Biomarker and Neuronal Therapeutic Target of a Disease-Improving Bile Acid in SCA3/MJD 2022
- The Glucocorticoid Receptor as a Biomarker and Neuronal Therapeutic Target of a Disease-Improving Bile Acid in SCA3/MJD 2022
- Motor coordination and balance ameliorated after treatment of the CMVMJD135 mouse model of Spinocerebellar Ataxia Type 3 with befiradol 2022
- Defining novel behavioural and neurophysiological features and testing a 5HT1A-targeting therapeutic agent in a clinically relevant mouse model of Rett Syndrome 2022
- Preclinical study of a 5-HT1A receptor specific agonist in the CMVMJD135 mouse model of Machado-Joseph disease. 2022
- The study of depression and cognitive comorbidities in a mouse model of spinocerebellar ataxia type 3 2022
- Pre and post-symptomatic treatment with NLX-112 improved the balance and motor coordination of the CMVMJD135 mouse model of Machado-Joseph Disease 2022
- Stress resilience in SCA3: study of depression and cognitive comorbidities in a mouse model 2022
- Role of the ubiquitin hydrolase ATXN3 in glioblastoma: a new tumor suppressor gene? 2022
- Befiradol treatment ameliorated the motor dysfunction of Spinocerebellar Ataxia Type 3 mouse model 2022
- Preclinical study of a 5-HT1A receptor specific agonist in the CMVMJD135 mouse model of Machado-Joseph disease 2022
- The study of depression and cognitive comorbidities in a mouse model of spinocerebellar ataxia type 3" 2022
- Understanding the relevance of the cerebellar cognitive affective syndrome in SCA3 mice 2022
- Can chronic activation of serotonergic signalling be atherapeutic approach for neurodegenerative diseases? 2021
- NLX-112 improved the motor coordination and balance in a Mouse Experimental Model of Machado-Joseph Disease 2021
- NLX-112 improved themotor coordination and balance in a Mouse Experimental Model of Machado-Joseph Disease 2021
- Intrathecal injection of secretome from anti-miR-124-treated ALS motor neurons in mSOD1 mice shows promise as a therapeutic strategy 2021
- Does activation of serotonergic treatment suppressproteotoxicity in mouse models of neurodegenerative diseases? 2021
- A comprehensive characterization of the cerebellar (dys)fucntion in Spinocerebellar Ataxia Type 3 2021
- A new lead compound for triple negative breast cancer therapy 2021
- MorphData: Automating the data extraction process of morphological features of microglial cells in ImageJ 2021
- Glucocorticoid receptor dysfunction as a SCA3/MJD biomarker and target for bile acid therapy 2021
- Testing the Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in an Animal Model of Spinocerebellar Ataxia Type 3 2021
- Serotonergic Signalling Activation as a Therapeutic Approach for Neurodegenerative Disorders 2021
- Serotonergic Signalling Activation as a Therapeutic Approach for Neurodegenerative Diseases 2021
- Towards the molecular determinants of serotonergic signaling-mediated suppression of SCA3 pathogenesis 2021
- Do MJD mice present a cerebellar cognitive affective syndrome? 2021
- Assessment of the Gastrointestinal Fate of Bacterial Cellulose and Its Toxicological Effects After Repeated-dose Oral Administration 2021
- Neuronal communication in Spinocerebellar Ataxia Type 3: a longitudinal characterization of the synapse 2020
- Impact of astrocytic calcium suppression in the pathogenesis of Machado-Joseph disease 2020
- Pre-clinical study of mesenchymal stem cells transplantation and their secretive administration in an animal model of Spinocerebellat ataxia type 3 2020
- The molecular tweezer CLR01 delay disease onset and reduce neurotoxicity in animal models of Machado-Joseph disease 2020
- Disease-modifying therapies for SCA3: lessons from preclinical trials 2019
- Impact of astrocytic calcium suppression in the pathogenesis of Machado Joseph disease 2019
- Pre-clinical assessment of Mesenchymal Stem cell-based therapies in Spinocerebellar ataxia type 3 2019
- Serotonergic signaling activation suppresses proteotoxicity 2019
- A Glucorticoid receptor-dependent mechanism of bile acid action with therapeutic impact in polyglutamine disease. 2019
- A Glucorticoid receptor-dependent mechanism of bile acid action with therapeutic impact in polyglutamine disease 2019
- Regulation of neuronal mRNA splicing and Tau isoform ratio by ATXN3 through deubiquitylation of splicing factors 2019
- Regulation of neuronal mRNA splicing and Tau isoform ratio by ATXN3 through deubiquitylation of splicing factors. 2019
- Microglial and astrocytic pathology in a mouse model of Machado-Joseph disease 2019
- In vitro and in vivo evaluation of new chromene derivatives as potent anticancer agents 2019
- Finding molecular determinants supporting serotonergic modulation as a therapeutic approach in Machado Joseph Disease 2019
- Regulation of neuronal mRNA splicing and Tau isoform by ATXN3 in Spinocerebellar Ataxia Type-3 transgenic mice and patients. 2019
- Pre-clinical study of mesenchymal stem cells transplantation and their secretome administration in an animal model of Spinocerebellar ataxia type 3 2019
- Cerebellar Dysfunction in Spinocerebellar Ataxia Type 3 2019
- Early modulation of serotonergic signaling suppresses aggregation in Spinocerebellar Ataxia 3 2019
- Preclinical evidence supporting serotonergic modulation as a therapeutic approach for Spinocerebellar Ataxia 3 2019
- Regulation of neuronal mRNA splicing and of Tau isoforms ratio by ATXN3 through deubiquitylation of splicing factors 2019
- Study of Cerebellar circuits (dys)function in Spinocerebellar Ataxia type 3 2019
- Testing the therapeutic potential of mesenchymal stem cells and their secretome in an animal model of SCA3 2019
- Testing the therapeutical potential of mesenchymal stem cells and their secretome in an animal model of SCA3 2019
- Finding molecular determinants supporting serotonergic modulation as a therapeutic approach in Machado-Joseph disease 2018
- Neuroprotective effects of creatine in the CMVMJD135 mouse model of spinocerebellar ataxia type 3 2018
- Preclinical evidence supporting early initiation of citalopram treatment in Machado-Joseph disease 2018
- TUDCA, a bile acid, improves the phenotype of Machado-Joseph disease models 2018
- Citalopram reduces aggregation of ATXN3 in a YAC transgenic mouse model of Machado-Joseph disease 2017
- Neuroinflammation assessment in a transgenic mouse model of Machado-Joseph disease 2017
- Serotonergic modulation of the proteostasis network and glutamatergic neurotransmission: impact on MJD 2017
- Serotonergic signaling suppresses ataxin-3 proteotoxicity 2017
- Time and region-specific glial pathology in mouse model of Machado-Joseph disease 2017
- Creatine food supplementation improves the phenotype and delays disease onset of the CMVMJD135 mouse model of Machado-Joseph disease. 2016
- Creatine-supplemented diet delays disease onset and improves the overall phenotype of the CMVMJD135 mouse model of MJD 2016
- TUDCA improves motor symptoms and reduces neuroinflammation in a transgenic mouse model of Machado-Joseph disease 2016
- Combined therapy with m-TOR-dependent and –independent autophagy inducers causes neurotoxicity in a mouse model of Machado-Joseph disease. 2015
- TUDCA improves motor symptoms and reduces neuroinflammation in a transgenic mouse model of Machado-Joseph disease 2015
- TUDCA reduces neuroinflammation and improves motor symptoms in a transgenic mouse model of Machado-Joseph disease 2015
- Testing Tauroursodeoxycholic Acid, a bile acid with neuroprotective action, in a mouse model of Machado-Joseph disease 2014
- 17-DMAG induces autophagy and delays disease progression in a mouse model of Machado-Joseph disease 2013
- Ataxin-3 deubiquitylase contributes to neuronal differentiation through the modulation of alpha-5 integrin levels 2013
- Autophagy induction as a therapeutic target for Machado-Joseph disease: 17-DMAG and lithium chloride 2013
- Loss of function of the deubiquitylase Ataxin-3 affects differentiation, proliferation and cytoskeletal organization in neuronal cells through the modulation of alpha-5 integrin subunit levels 2013
- Loss of function of the deubiquitylase Ataxin-3 reduces alpha-5 integrin subunit levels and leads to an abnormal neuronal differentiation process 2013
- 17-DMAG and Valproic Acid improve the phenotype of a new transgenic mouse model of Machado-Joseph disease 2012
- 17-DMAG, an Hsp90 inhibitor, improves the motor phenotype and neuropathology of a transgenic mouse model of Machado-Joseph disease 2012
- 17-DMAG, an Hsp90 inhibitor, improves the phenotype of a new transgenic mouse model of Machado-Joseph disease 2012
- Lithium treatment does not ameliorate the phenotype of a new transgenic mouse model of Machado-Joseph 2012
- A novel transgenic mouse model of Machado-Joseph disease: genetic, phenotypic and pathologic similarities with the human disease 2011
- Region-specific transcriptomic profile alterations in a new transgenic mouse model of Machado-Joseph disease 2011
- Detecção de Yersinia enterocolitica em carne de porco picada - Comparação de três metodologias, com vários tempos de enriquecimento da amostra 2010
- A novel transgenic mouse model of Machado-Joseph disease: autophagy as a potential therapeutical approach 2010
- CAG tract length modulates the severity of symptoms in a transgenic mouse model of MJD/SCA3 2010
- No evidence for apoptosis or necrosis in spite of neurodegeneration in a transgenic mouse model of MJD/SCA3 2010
- Detection of Yersinia enterocolitica in raw pork by conventional culture methods and PCR based methods 2009
- Aging, Genetic Background and parental gender modulate the CAG repeat instability pattern in a transgenic mouse model of Machado-Joseph disease 2009
- Motor impairment and brain pathology in a transgenic mouse model of Machado-Joseph disease 2008
- Genetic interaction between Machado-Joseph disease mutant gene and age-related cellular quality control mechanisms 2007
- Efficacy of chronic 5-HT 1A receptor agonism by NLX-112 in a mouse model of Spinocerebellar Ataxia type 3
- The 5-HT 1A receptor agonist NLX-112 rescues motor swimming deficits in Spinocerebellar Ataxia type 3 mice
- Understanding corticosterone fluctuations and HPA-axis regulation in a mouse model of Spinocerebellar ataxia type 3
-
livro
-
teses